CRIS Current Research Information System

MAZZELLA, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.245
EU - Europa 6.143
AS - Asia 3.133
AF - Africa 378
SA - Sud America 29
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 2
Totale 18.945
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.221
GB - Regno Unito 1.941
CN - Cina 1.112
IT - Italia 843
SE - Svezia 842
DE - Germania 809
SG - Singapore 772
VN - Vietnam 674
UA - Ucraina 392
IN - India 388
IE - Irlanda 298
RU - Federazione Russa 267
FR - Francia 263
EE - Estonia 160
ZA - Sudafrica 147
CH - Svizzera 102
TG - Togo 91
BG - Bulgaria 64
CI - Costa d'Avorio 60
JO - Giordania 45
NG - Nigeria 40
GR - Grecia 35
SC - Seychelles 32
JP - Giappone 30
BE - Belgio 29
CA - Canada 24
IR - Iran 22
NL - Olanda 20
FI - Finlandia 19
KR - Corea 18
BR - Brasile 15
PL - Polonia 15
PK - Pakistan 13
AU - Australia 11
ID - Indonesia 11
LB - Libano 9
CZ - Repubblica Ceca 8
AT - Austria 7
EG - Egitto 6
AR - Argentina 5
HK - Hong Kong 5
HR - Croazia 5
TR - Turchia 5
CL - Cile 4
DK - Danimarca 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
RO - Romania 4
UZ - Uzbekistan 4
ES - Italia 3
IL - Israele 3
IQ - Iraq 3
MM - Myanmar 3
MY - Malesia 3
PH - Filippine 3
SA - Arabia Saudita 3
SI - Slovenia 3
BD - Bangladesh 2
EC - Ecuador 2
EU - Europa 2
MD - Moldavia 2
MK - Macedonia 2
PE - Perù 2
PT - Portogallo 2
AE - Emirati Arabi Uniti 1
DZ - Algeria 1
KW - Kuwait 1
LK - Sri Lanka 1
TH - Thailandia 1
TN - Tunisia 1
TW - Taiwan 1
VE - Venezuela 1
Totale 18.945
Salva come PNG Salva come JPEG
Città #
Southend 1.800
Fairfield 1.357
Chandler 859
Singapore 675
Ashburn 671
Wilmington 514
Woodbridge 502
Houston 477
Seattle 465
Santa Clara 458
Dong Ket 439
Princeton 387
Cambridge 370
Ann Arbor 303
Dublin 298
Boardman 262
Jacksonville 241
Bologna 183
Westminster 177
Nanjing 173
Padova 149
Saint Petersburg 115
Berlin 110
Lomé 91
Medford 87
New York 85
Bern 78
Jinan 74
Shenyang 73
Dearborn 67
Hebei 64
Beijing 62
Sofia 61
Abidjan 60
San Diego 58
Milan 54
Nanchang 53
Changsha 48
Amman 45
Bremen 45
Mülheim 41
Abeokuta 40
Shanghai 37
Des Moines 33
Florence 32
Tianjin 31
Turin 31
Mahé 29
Jiaxing 28
Redwood City 28
Brussels 27
Guangzhou 27
Falls Church 25
Frankfurt am Main 25
Pune 25
Redmond 25
Tokyo 25
Hangzhou 23
Norwalk 21
Haikou 20
Ningbo 20
Olalla 20
Zhengzhou 20
Helsinki 19
Kunming 18
Mountain View 18
Taizhou 18
Fuzhou 16
Los Angeles 16
Lanzhou 15
Verona 15
Shenzhen 14
Monmouth Junction 13
Toronto 13
Chengdu 12
Washington 12
Wuhan 12
Bühl 11
Leawood 11
Phoenix 11
Catania 10
Jakarta 10
London 10
Torino 10
Groningen 9
San Francisco 9
Ardabil 8
Lausanne 8
Paris 8
Xi'an 8
Andover 7
Augusta 7
Bari 7
Hanover 7
Jeju City 7
Lahore 7
Rome 7
São Paulo 7
Castelnuovo Rangone 6
Kuban 6
Totale 13.125
Salva come PNG Salva come JPEG
Nome #
A new model for portal protein profile analysis in course of ileal intraluminal bile acid infusion using an in situ perfused rat intestine. 248
A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis 217
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 212
Antiinflammatory Effect of Phytosterols in Experimental Murine Colitis Model: Prevention, Induction, Remission Study 196
G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence 185
Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. 183
A RETROSPECTIVE STUDY ON INTRAHEPATIC CHOLESTASIS OF PREGNANCY: MARKERS OF PREMATURE DELIVERY 174
Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. 172
Curcuma longa Extract Exerts a Myorelaxant Effect on the Ileum and Colon in a Mouse Experimental Colitis Model, Independent of the Anti-Inflammatory Effect 170
The future of dual therapy for hepatitis C virus 164
Correlazione materno-fetale degli acidi biliari in corso di colestasi gravidica 162
Adverse effects of proton pump inhibitors. 160
Berberine and its metabolites: Relationship between physicochemical properties and plasma levels after administration to human subjects 159
Complete Remission of Advanced Hepatocellular Carcinoma Treated with Sorafenib and Concomitant Appearance of IgG4- related Diseases. A Case Report 153
High Doses of Ursodeoxycholic Acid Up-Regulate the Expression of Placental Breast Cancer Resistance Protein in Patients Affected by Intrahepatic Cholestasis of Pregnancy 150
Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension 148
Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals 146
Alisporivir for the treatment of chronic HCV 144
Generation of a novel antibody probe to the Apical Sodium-Dependent Bile Acid Transporter that inhibits ileal bile acid absorption 142
Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis 141
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence. 140
Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. 137
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 136
CMV infection and biliary tract complications are related with a poor outcome of liver transplantation for HCV-related cirrhosis 134
Curcuma longa L. as a therapeutic agent in intestinal motility disorders. 2: Safety profile in mouse. 134
The impact of assisted reproductive technology and chorionicity in twin pregnancies complicated by obstetric cholestasis 132
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 132
Chronic NSAIDs Therapy and Upper Gastrointestinal Tract – Mechanism of Injury, Mucosal Defense, Risk Factors for Complication Development and Clinical Management 131
Severe immune thrombocytopenia after peg-interferonalpha2a, ribavirin and telaprevir treatment completion: A case report and systematic review of literature 131
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 130
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 129
Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study 128
IL28 polymorphism and HCC after DAAs for chronic hepatitis C 127
Ribavirin for chronic hepatitis C: And the mystery goes on. 126
Direct acting antivirals for the treatment of elderly patients with HCV advanced disease in the real life practice 126
Correlation between Indocyanine green retention test and esophageal varices among patients with hepatocellular carcinoma 126
Colonic gallstone ileus treated with radiologically guided xtracorporeal shock wave lithotripsy followed by endoscopic extraction. 124
An unusual cause of weight loss in a young Caucasian man 123
Treatment with direct acting antiviral agents-based regimen in HCV patients with advanced liver disease: Analysis of an Italian multicenter observational study 123
Mathematical model predicting high hepatocyte proliferation index and risk of HCC in patients with HCV related cirrhosis: a proposal for clinical validation 123
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 122
Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B 121
Management of hepatic encephalopathy: focus on antibiotic therapy 121
AISF position paper on liver disease and pregnancy 120
Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients 119
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 118
Regolazione dei trasportatori placentari degli acidi biliari MRP2, MRP3, MRP4 da parte dell’acido ursodesossicolico in corso di colestasi gravidica 117
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial 117
Terapia cellulare in Epatologia 115
Breath tests with stable isotopes: have they a role in liver transplantation? 115
Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients 115
Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: a prospective study 115
Ductal stones recurrence after extracorporeal shock wave lithotripsy for difficult common bile duct stones: Predictive factors 113
Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients 113
Noninvasive diagnosis of portal hypertension and esophageal varices through the identification of liver blood flow markers 112
Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients 112
Proton pump inhibitors in cirrhosis: tradition or evidence based practice? 111
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease. 111
High incidence of allograft dysfunction in liver transplant patients treated with PEG-Interferon alfa-2b and Ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? 110
G-CSF administration is not related to PEG-IFN alfa-213 treatment duration nor response in liver transplanted patients with HCV recurrence 110
Spleen stiffness measurement: A useful prognostic tool in HCV patients treated with DAAs regimens 110
Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis 110
Pharmacological modulation of MRP2 in primary biliary cirrhosis 108
P.09.6 IL28 POLYMORPHISM AND HCC DEVELOPMENT AFTER DAAS FOR CHRONIC HEPATITIS C 108
Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update 108
null 107
null 107
Systemic fungemia and hepatic localizations of Fusarium solani in a liver transplanted patient: An emerging fungal agent. 107
Efficacy of ursodeoxycholic acid administration on clinical manifestations of gallstones and gastrointestinal motility 106
Interleukin 28 polymorphisms and hepatocellular carcinoma development after direct acting antiviral therapy for chronihepatitis c 105
Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation. 104
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 104
Hypertransaminasemia and pregnancy outcome. 103
Identification of Naïve Hcv-1 Patients with Chronic Hepatitis who may Benefit from Dual Therapy with Peg-Interferon and Ribavirin. 102
Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. 101
Extracorporeal shock wave lithotripsy for difficult common bile duct stones: a comparison between 2 different lithotripters in a large cohort of patients. 101
Mathematical model predicting high hepatocyte proliferation index and risk of HCC in patients with HCV related cirrhosis: a proposal for clinical validation 101
Superior efficacy of twice a week administration of peginterferon alpha-2b plus ribavirin in obtaining SVR in HCV genotype 1 100
Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations 100
Hepatobiliary phospholipid transporter ABCB4, MDR3 gene variants in a large cohort of Italian women with intrahepatic cholestasis of pregnancy 100
Chemiluminescence measurement of autotaxin activity in human serum 100
Severe acute autoimmune hepatitis after natalizumab treatment. 100
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) 100
THU-490 - Spleen stiffness measurement: a useful prognostic tool in HCV patients treated with DAAs regimens 99
Persistent Fever and Abdominal Pain in a Young Woman With Budd-Chiari Syndrome 99
Safety of interferon beta treatment for chronic HCV hepatitis. 98
High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on 98
MRP2 is upregulated by UDCA in cholestasis of pregnancy. 98
Incidence of gallstone disease in Italy: Results from a multicenter, population-based Italian study (the MICOL project). 98
Indocyanine Green 15-min Retention test (ICG-r15) as a predictor of clinical decompensation in patients with compensated liver cirrhosis. 98
Indocyanine green clearance as a marker of decompensation and clinically significant portal hypertension in patients with liver cirrhosis. 98
null 96
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 96
Small (≤3cm) Hepatocellular Carcinoma in Cirrhosis: the Role of Double Contrast Agents MR Imaging vs. Multi-Detector Row CT 95
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 95
THU-492 - Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in hepatocellular carcinoma development in in cirrhotic patients 95
A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices 95
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome 94
Indocyanine green clearance as a marker of decompensation and clinically significant portal hypertension in patients with liver cirrhosis 94
Genetic polymorphisms of PPAR-alpha: allele frequency in gallstone patients. 93
Totale 12.356
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.782
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.782
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.433 0 0 0 0 441 488 572 611 575 295 168 283
2020/20212.416 502 167 76 79 59 83 46 150 243 138 111 762
2021/20223.802 325 146 205 235 332 196 88 204 138 171 1.187 575
2022/20233.513 422 492 202 473 234 276 92 178 615 85 241 203
2023/20241.008 70 163 58 121 84 244 37 52 72 60 21 26
2024/20252.128 155 695 357 242 679 0 0 0 0 0 0 0
Totale 19.366